Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the “Company”) will be held at the Company’s offices at Lysaker, on 20 April 2022 at 16:00 CET.

Notice of attendance

Notice of attendance must be received no later than 19 April 2022 at 16:00 CET.

Casting of advance votes and submission of proxies must be received no later than 19 April 2022 at 16:00 CET.

Attached you will find the notice to the General Meeting, including appendices. The notice and appendices will also be made available on Targovax’ website https://www.targovax.com/en/section/governance/general-meetings/.

TRVX – Notice AGM 20.04.2022.pdf

For further information, please contact:
Lubor Gaal, CFO
Phone: +34 683 343 811

Email: lubor.gaal@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and providing deep mechanistic insights, Targovax is expanding its ONCOS program into delivery of circular RNA and targeting KRAS mutant cancers with the aim of establishing a platform for development of a rich pipeline of innovative future immunotherapy product candidates.